Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
9.24
-2.27 (-19.70%)
Mar 31, 2025, 2:29 PM EDT - Market open
Capricor Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Capricor Therapeutics stock have an average target of 39.29, with a low estimate of 25 and a high estimate of 77. The average target predicts an increase of 325.45% from the current stock price of 9.24.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Capricor Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +224.85% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $77 | Strong Buy | Reiterates | $77 | +733.78% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $77 | Strong Buy | Reiterates | $77 | +733.78% | Mar 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $77 | Strong Buy | Reiterates | $77 | +733.78% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $77 | Strong Buy | Reiterates | $77 | +733.78% | Jan 2, 2025 |
Financial Forecast
Revenue This Year
29.92M
from 22.27M
Increased by 34.33%
Revenue Next Year
103.72M
from 29.92M
Increased by 246.72%
EPS This Year
-0.96
from -1.15
EPS Next Year
0.07
from -0.96
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 150.7M | 170.5M | 334.4M | ||
| Avg | 29.9M | 103.7M | 178.7M | ||
| Low | n/a | 39.2M | 43.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 576.6% | 470.0% | 222.4% | ||
| Avg | 34.3% | 246.7% | 72.3% | ||
| Low | - | 31.0% | -58.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.71 | 1.44 | 2.31 | ||
| Avg | -0.96 | 0.07 | 1.24 | ||
| Low | -1.60 | -1.18 | -0.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 3,070.5% | ||
| Avg | - | - | 1,597.5% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.